Posted by Michael Wonder on 22 Jul 2025
Health Canada approves Keytruda for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy
21 July 2025 - Approval is based on the results from Phase 3 KEYNOTE-A18/ENGOT-cx11/GOG-30472
Merck announced today that Health Canada has granted approval for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 stage III-IVA cervical cancer.
